Stonehage Fleming Financial Services Holdings Ltd Purchases Shares of 2,551 Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Stonehage Fleming Financial Services Holdings Ltd acquired a new position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 2,551 shares of the medical device company’s stock, valued at approximately $92,000.

Several other large investors have also recently modified their holdings of the company. Brooklyn Investment Group purchased a new position in Tandem Diabetes Care in the third quarter worth $28,000. Assetmark Inc. purchased a new position in Tandem Diabetes Care during the 3rd quarter worth $29,000. ORG Wealth Partners LLC purchased a new stake in Tandem Diabetes Care in the third quarter valued at about $30,000. Waldron Private Wealth LLC acquired a new stake in Tandem Diabetes Care in the third quarter worth about $50,000. Finally, McIlrath & Eck LLC purchased a new stake in shares of Tandem Diabetes Care during the third quarter worth about $52,000.

Insider Activity

In other news, Director Kim D. Blickenstaff sold 10,000 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the sale, the director now owns 195,190 shares in the company, valued at approximately $5,855,700. This represents a 4.87 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 2.20% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Robert W. Baird lowered their price objective on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating for the company in a research note on Thursday, November 7th. Barclays boosted their price target on Tandem Diabetes Care from $58.00 to $60.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. Canaccord Genuity Group reduced their price objective on Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Sanford C. Bernstein assumed coverage on Tandem Diabetes Care in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $42.00 target price on the stock. Finally, Royal Bank of Canada initiated coverage on shares of Tandem Diabetes Care in a research report on Wednesday, October 2nd. They set an “outperform” rating and a $65.00 price target for the company. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $53.81.

Tandem Diabetes Care Trading Up 2.8 %

NASDAQ:TNDM opened at $36.50 on Monday. Tandem Diabetes Care, Inc. has a fifty-two week low of $21.85 and a fifty-two week high of $53.69. The firm’s 50 day moving average is $34.15 and its two-hundred day moving average is $37.70. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.08. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company had revenue of $243.97 million during the quarter, compared to analyst estimates of $224.14 million. During the same quarter in the prior year, the business earned ($0.38) earnings per share. The business’s quarterly revenue was up 31.4% compared to the same quarter last year. On average, equities research analysts predict that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.